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 Re: Adjuvant Treatment of 
High-Risk, Radically 
Resected Gastric Cancer 
Patients with 5-Fluorouracil, 
Leucovorin, Cisplatin, and 
Epidoxorubicin in a 
Randomized Controlled Trial 
 We read with great interest the recent article 
by Cascinu et al. ( 1 ). The authors compared 
an 8-week intensive platinum, epirubicin, 
leucovorin, fluorouracil regimen (PELFw) 
with a much less intensive “control” 5-fluo-
rouracil/leucovorin regimen in patients with 
radically resected locally advanced gastric 
cancer ( 1 ) and reported no difference in 
terms of overall survival and disease-free 
survival. The negative results of this trial 
could be due to several reasons, including 
the lack of new drugs in the experimental 
arm and inadequate sample size. Never-
theless, the take-home message of the 
authors is that intensive adjuvant chemo-
therapy is ineffective and uselessly toxic, 
and, therefore, they suggest a move toward 
a preoperative setting of investigation. 
 Other trials have revealed the problems 
of postoperative intensive chemotherapy; 
among them, the Medical Research Council 
Adjuvant Gastric Infusional Chemother-
apy trial ( 2 ) showed that perioperative 
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chemotherapy with ECF (epirubicin, cispla-
tin, 5-ﬂ uorouracil) improves survival com-
pared with surgery alone, although we cannot 
know if this advantage derives from preop-
erative or postoperative treatment or both. 
Based on the report of Cascinu et al. ( 1 ), we 
cannot know if the PELFw chemotherapy 
regimen is equally effective as the 5-ﬂ uoro-
uracil/leucovorin regimen or if both are 
totally ineffective, given the lack of an obser-
vation-only arm. We agree with the authors 
that the unexpectedly high survival rate 
observed could be due to adequate nodal 
dissection, as previously shown in the Italian 
Trials of Medical Oncology trial ( 3 ), where 
the surgery-alone arm produced a 48% 
5-year survival rate after D2-dissection. 
 Another important message from the 
study of Cascinu et al. ( 1 ) is the uselessness 
of radiotherapy after high-quality surgery, 
as suggested by the low local recurrence 
rate. This is a further demonstration that 
the American standard option of adjuvant 
chemoradiotherapy, derived from the study 
of Macdonald et al. ( 4 ), is not applicable to 
the Italian reality. 
 The authors ’ conclusions conﬁ rm our 
experimental approach of some years 
ago, when we designed a randomized trial 
comparing preoperative versus post oper-
ative therapy with a taxotere/cisplatin/ 
5-fluorouracil combination in radically 
resected locally advanced gastric cancer 
patients. This study, born from a coopera-
tion between the Swiss Group for Cancer 
Research and the European Institute of 
Oncology in Milan, found that preoperative 
therapy was better tolerated and more 
feasible compared with postoperative therapy 
(unpublished data) but did not furnish useful 
information on relative efﬁ cacy because it 
was prematurely stopped due to slow accrual. 
Neoadjuvant studies are much more difﬁ cult 
than adjuvant ones, requiring a high level 
of multidisciplinary management. This is 
demonstrated by the fact that the conclusions 
from the trial of Cascinu et al. ( 1 ) were not 
applied even by the same investigative insti-
tutions involved in the trial. Indeed, many of 
them preferred to participate in an ongoing 
two-arm adjuvant Italian intergroup trial 
with a large accrual goal of 1100 patients 
to obtain statistical evidence in favor of an 
intensive new drug postoperative chemo-
therapy that was missing in the PELFw trial. 
In conclusion, given the increased investiga-
tive focus toward a preoperative setting in 
resectable gastric cancer, the time is ripe to 
conduct a large, international multicentric 
randomized phase III trial of a new-drug 
neoadjuvant chemotherapy regimen involv-
ing all major reference groups. 
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shared. Our data, along with those deriv-
ing from the Medical Research Council 
Adjuvant Gastric Infusional Chemotherapy 
(MAGIC) trial, seem to indicate that a bet-
ter tolerability profile of a perioperative 
treatment approach is resp onsible, at least 
in part, for the improved outcome ( 2 ). 
However, when our trial was designed, 
about 10 years ago, this was not a wide-
spread opinion. At about the same time, 
the Swiss Group designed a clinical trial 
comparing a preoperative versus a post-
operative chemotherapeutic approach with 
a regimen that included docetaxel. 
Unfortunately, at that time definitive data 
about activity and tolerability of docetaxel 
as a treatment for gastric cancer were 
largely lacking, making the trial design 
somewhat problematic. In fact, it was only 
last year that a randomized trial clarified 
the role of docetaxel in gastric cancer ( 3 ). 
Furthermore, our trial was designed before 
the MAGIC trial, when data from pub-
lished literature seemed to largely support 
a postoperative approach ( 4 ). However, we 
believe that even positive results obtained 
with a preoperative approach may require 
cautious interpretation. It is important to 
consider that the 5-year survival in the 
MAGIC trial was only 23% in the control 
arm and 36% in the treatment arm, whereas 
the 5-year survival approached 50% in the 
control arms, both in our study and in the 
Italian Trials of Medical Oncology trial ( 5 ). 
Once again, potentially positive results may 
depend on the quality of surgery, and adju-
vant treatment may be useful only in 
patients not likely to receive an optimal 
surgical treatment. We note that a similar 
interpretation was applied to results 
obtained with adjuvant radiotherapy in the 
trial of MacDonald et al. ( 6 ). 
 Finally, Fazio et al. seem to question the 
choice by the Italian Intergroup to carry 
out a new postoperative therapy with a 
chemotherapy including 5-ﬂ uorouracil, 
cisplatin, irinotecan, and docetaxel in a 
sequential manner. Although we agree with 
most of the comments and concerns raised 
in the letter, we think that this new trial is 
exploring a novel treatment strategy in 
gastric cancer by allowing the administra-
tion of several drugs but, at the same time, 
limiting their toxic effects. The sequential 
multidrug approach is biologically different 
from the intensive approach evaluated in 
our study and could not be explored with a 
 Response 
 We have read with interest the correspon-
dence regarding the role of pre- and post-
operative chemotherapy in gastric cancer 
in response to our recent report of an 
intensive adjuvant chemotherapy in gastric 
cancer ( 1 ). The idea that preoperative 
chemotherapy may be a more suitable 
treatment approach for locally advanced 
gastric cancer is, in fact, now widely 
neoadjuvant design. Preliminary safety data 
from this trial are encouraging. If this 
approach also fails to show any advantage, 
preoperative chemotherapy would be the 
only viable treatment strategy to pursue in 
the future. 
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